SciMar
SciMar Ltd. is a Manitoba-based biotech company dedicated to changing how the world prevents, detects, and treats type 2 diabetes through groundbreaking science and holistic lifestyle interventions. Founded in 2009, it leverages the scientific discoveries of Dr. W. Wayne Lautt, including the hormone hepatalin, to develop innovative therapies and diagnostics aimed at ending the global diabetes epidemic. The company engages in clinical trials, product development, community outreach, and investor relations, with a mission to revolutionize diabetes care and improve metabolic health worldwide. The company is actively seeking investment opportunities to fund its pharmaceutical products and innovative distribution channels, with multiple revenue streams and potential liquidity opportunities within the next seven years.
Industries
Nr. of Employees
small (1-50)
SciMar
Patents
Hepatic insulin sensitizing substance and test meal for insulin sensitization
US-9840547-B2
View DetailsUse of S-adenosylmethionine, vitamin E, and vitamin C for the treatment of oxidative liver injury
US-8716260-B2
View DetailsUse of S-adenosylmethionine, vitamin E, and vitamin C for the treatment of oxidative liver injury and insulin resistance
US-8063024-B2
View DetailsTreatment of insulin resistance by modulating somatostatin using somatostatin receptor antagonists
US-8017575-B2
View Details
Hepatic insulin sensitizing substance and test meal for insulin sensitization
US-9840547-B2
View DetailsUse of S-adenosylmethionine, vitamin E, and vitamin C for the treatment of oxidative liver injury
US-8716260-B2
View DetailsUse of S-adenosylmethionine, vitamin E, and vitamin C for the treatment of oxidative liver injury and insulin resistance
US-8063024-B2
View DetailsTreatment of insulin resistance by modulating somatostatin using somatostatin receptor antagonists
US-8017575-B2
View DetailsProducts
Diagnostic test-meal protocol and prototype
A standardized diagnostic meal protocol and prototype product to measure postprandial biomarker release as an early indicator of metabolic dysfunction; prototype advanced into Phase 2 clinical testing.
Oral antioxidant nutraceutical
A daily oral antioxidant formulation intended to support liver function and protect postprandial biomarker production; sold as a nutraceutical with planned clinical evaluation to support label claims.
Pre-meal pharmaceutical candidate
An oral pharmaceutical candidate intended for administration immediately before meals to stimulate postprandial biomarker release and restore nutrient partitioning; in preparation for Phase 2B clinical trials.
Synthetic peptide/protein therapeutic candidate
A synthetic peptide/protein therapeutic candidate intended for administration as replacement or adjunct therapy for advanced-stage metabolic disease; development and patent protection are in progress.
Diagnostic test-meal protocol and prototype
A standardized diagnostic meal protocol and prototype product to measure postprandial biomarker release as an early indicator of metabolic dysfunction; prototype advanced into Phase 2 clinical testing.
Oral antioxidant nutraceutical
A daily oral antioxidant formulation intended to support liver function and protect postprandial biomarker production; sold as a nutraceutical with planned clinical evaluation to support label claims.
Pre-meal pharmaceutical candidate
An oral pharmaceutical candidate intended for administration immediately before meals to stimulate postprandial biomarker release and restore nutrient partitioning; in preparation for Phase 2B clinical trials.
Synthetic peptide/protein therapeutic candidate
A synthetic peptide/protein therapeutic candidate intended for administration as replacement or adjunct therapy for advanced-stage metabolic disease; development and patent protection are in progress.
Services
A networked clinical-research platform that integrates community partners to run lifestyle interventions, recruit participants, and collect trial data for biomarker-driven studies.
Studio-style services offering research completion support, collaboration facilitation, marketing and investor engagement, and pathways to clinical testing for early-stage life-science projects.
A networked clinical-research platform that integrates community partners to run lifestyle interventions, recruit participants, and collect trial data for biomarker-driven studies.
Studio-style services offering research completion support, collaboration facilitation, marketing and investor engagement, and pathways to clinical testing for early-stage life-science projects.
Expertise Areas
- Clinical trial management (acute biomarker and crossover designs)
- Proteomics and mass spectrometry analytics
- Biomarker assay development and translation
- Nutraceutical and small-molecule formulation
Key Technologies
- Mass spectrometry
- Proteomics workflows
- Biomarker assay development
- Crossover and acute clinical trial methodologies
News & Updates
Staff Spotlight
Behind the Science: A Spotlight on Scimar’s Director of Preclinical Research
Podcasts
Six Blind Men and the Elephant
Podcasts
Black Swan Theory
Interested in learning more about Scimar’s clinical trials program?
Click here for more information
Traditional Territories Acknowledgement
Scimar’s corporate head office is located in Dauphin, Manitoba, with research facilities in Winnipeg. The company operates throughout Manitoba on the traditional territories of Indigenous nations and the Métis people.
The Latest
Updates on staff, podcasts, and scientific progress.
Staff Spotlight
Behind the Science: A Spotlight on Scimar’s Director of Preclinical Research
Podcasts
Six Blind Men and the Elephant
Podcasts
Black Swan Theory
Interested in learning more about Scimar’s clinical trials program?
Click here for more information
Traditional Territories Acknowledgement
Scimar’s corporate head office is located in Dauphin, Manitoba, with research facilities in Winnipeg. The company operates throughout Manitoba on the traditional territories of Indigenous nations and the Métis people.
The Latest
Updates on staff, podcasts, and scientific progress.